Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

naphazoline hydrochloride

ALBALON

naphazoline hydrochloride (ALBALON) is a adrenergic receptor alpha agonist. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 13
Pipeline programs 4
News articles 0
Drug details — naphazoline hydrochloride
US status
approved
Class
—
Route
OPHTHALMIC
Patents
13
Programs
4
Data quality
0.84
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

naphazoline hydrochloride (ALBALON) is a adrenergic receptor alpha agonist. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN naphazoline hydrochloride
Brand ALBALON
Mechanism Adrenergic receptor alpha agonist
Target Adrenergic receptor alpha
Route OPHTHALMIC
Formulation SOLUTION/DROPS

Mechanism of action

Adrenergic receptor alpha agonist

Primary target: Adrenergic receptor alpha

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline
  1. CB-03-01/39 Phase 1 · Cassopeia Pharmaceuticals Pvt · Test of vasocontriction properties for classification of top
  2. Cocaine hydrochloride Phase 1 · BRIGHT MINDS BIOSCIENCES · Cocaine Induced Sympathoexciation and Vasoconstriction
  3. placebo (compared to vasoconstrictor) Unknown · Chinese Academy of · Healthy Adult Male
  4. vasoconstrictor and oxytocin treatment Unknown · Chinese Academy of · Healthy

Related & competitor drugs

Browse all drugs
  1. brimonidine tartrate Adrenergic receptor alpha-2 agonist
  2. carvedilol Adrenergic receptor beta antagonist
  3. clonidine hydrochloride Adrenergic receptor alpha-2 agonist
  4. dexmedetomidine hydrochloride Adrenergic receptor alpha-2 agonist
  5. doxazosin mesylate Adrenergic receptor alpha-1 antagonist
  6. guanfacine hydrochloride Adrenergic receptor alpha-2 agonist

Related patents

Browse patents

  1. WO 2025125508

    COMBINAISONS DE CORTEXOLONE-17ΑLPHA-PROPIONATE POUR LE TRAITEMENT DE L'ACNÉ

    Expires Wed Jun 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2025068281

    CORTÉXOLONE-17α-PROPIONATE POUR LE TRAITEMENT D'ÉRUPTIONS ACNÉIFORMES

    Expires Wed Mar 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. EP 4529925

    CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN

    Expires Tue Mar 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12156862

    Medicaments for the treatment of vasoconstriction related diseases or disorders

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9555037

    Method of using vasoconstrictive agents during energy-based tissue therapy

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9271985

    Method of using vasoconstrictive agents during energy-based tissue therapy

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. CA 2934118

    PROPIONATE DE CORTEXOLONE-17' DESTINE A ETRE UTILISE DANS LE TRAITEMENT DE LESIONS CUTANEES ET/OU DE TROUBLES DE LA PEAU ATROPHIQUE

    Expires Wed Jun 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8968234

    Method of using vasoconstrictive agents during energy-based tissue therapy

    Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8945108

    Method of using vasoconstrictive agents during energy-based tissue therapy

    Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8202242

    Method of using vasoconstrictive agents during energy-based tissue therapy

    Expires Mon Jun 14 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7109245

    Vasoconstrictor cannabinoid analogs

    Expires Mon Sep 14 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. AU 2005207635

    Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds

    Expires Wed Jul 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  13. US 6365725

    DNA coding for a human vasoconstrictive peptide and use thereof

    Expires Mon Mar 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is naphazoline hydrochloride?

naphazoline hydrochloride (ALBALON) is a adrenergic receptor alpha agonist. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for naphazoline hydrochloride?

ALBALON is a marketed brand name for naphazoline hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of naphazoline hydrochloride?

naphazoline hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.